#ROS1 Presentations at ESMO 2017

The European Society for Medical Oncology will hold their annual Congress in Madrid, Spain, on September 8-12 this year.  The three presentations that will discuss ROS1 specifically are listed below (you can see the complete abstracts by clicking on the presentation title).

1308PD – Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC).  Lorlatinib showed clinical activity in ROS1+ NSCLC patients, a majority of whom had central nervous system involvement and most of whom had received prior crizotinib. Overall, lorlatinib was well-tolerated.

1362P – Safety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene.  DS-6051b is well tolerated in Japanese patients with ROS-rearranged non-small cell lung cancer, and more effective in patients who have not taken crizotinib. The maximum tolerated dose was set at 600mg twice daily.

1337P – A meta-analysis on epidemiology of ROS1 rearrangement in Asian and non-Asian population

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.